Biological Activity:

ORY-1001 is a highly potent and selective inhibitor of Lysine Specific Demethylase 1 (LSD1) with IC50 <20 nM. It is highly selective over related enzymes such as MAO-A/B. ORY-1001 affects AML stem cells, a sub-population of cancer cells that has been proposed to be responsible for frequent relapses of the disease. It significantly reduces tumor cell load and increases survival time in mouse models of Acute Lymphoblastic Leukaemia. Currently ORY-1001 is in Phase I/IIA clinical trial for acute leukemia.

How to Use:

In vitro: ORY-1001 was used at 1 µM in vitro.
In vivo: n/a.

Reference:

• 1. https://www.oryzon.com/en/therapeutic-programs/our-pipeline